全文获取类型
收费全文 | 1622篇 |
免费 | 194篇 |
国内免费 | 41篇 |
出版年
2024年 | 4篇 |
2023年 | 57篇 |
2022年 | 47篇 |
2021年 | 71篇 |
2020年 | 104篇 |
2019年 | 161篇 |
2018年 | 97篇 |
2017年 | 58篇 |
2016年 | 68篇 |
2015年 | 92篇 |
2014年 | 123篇 |
2013年 | 165篇 |
2012年 | 84篇 |
2011年 | 83篇 |
2010年 | 70篇 |
2009年 | 55篇 |
2008年 | 69篇 |
2007年 | 48篇 |
2006年 | 49篇 |
2005年 | 29篇 |
2004年 | 45篇 |
2003年 | 19篇 |
2002年 | 35篇 |
2001年 | 26篇 |
2000年 | 17篇 |
1999年 | 18篇 |
1998年 | 17篇 |
1997年 | 11篇 |
1996年 | 16篇 |
1995年 | 11篇 |
1994年 | 18篇 |
1993年 | 16篇 |
1992年 | 11篇 |
1991年 | 9篇 |
1990年 | 5篇 |
1989年 | 9篇 |
1988年 | 5篇 |
1987年 | 9篇 |
1986年 | 2篇 |
1985年 | 6篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 5篇 |
1976年 | 1篇 |
排序方式: 共有1857条查询结果,搜索用时 15 毫秒
11.
Recent approaches toward the immunotherapy of neoplastic disease involve the introduction of expression-competent genes for interleukin-2 (IL-2) into autologous malignant cells. Treatment of tumor-bearing experimental animals with the IL-2-secreting cells successfully induces partial and at times complete remissions. In most instances, however, although delayed, progressive tumor growth continues. Here, certain of the characteristic of B16 melanomas (H-2b) persisting in C57BL/6 mice (H-2b) treated with an IL-2-secreting, melanoma-antigen-positive cellular immunogen (RLBA-IL-2 cells) are described. Unlike the melanoma cells first injected, B16 cells recovered from mice treated with RLBA-IL-2 cells were deficient in the experssion of MHC class I, but not class II determinants. Deficient MHC class I expression correlated with the cells' resistance to cytotoxic T lymphocytes (CTL) from the spleens of mice immunized with RLBA-IL-2 cells. Melanomas persisting in mice treated with non-IL-2-secreting, melanoma-antigen-positive cell constructs (RLBA-ZipNeo cells) were also deficient in the expression of MHC class I determinants, and the melanoma cells were resistant to CTL from mice immunized with RLBA-ZipNeo cells. Thus, the expression of melanoma-associated antigens rather than IL-2-secretion correlated with deficient MHC class I expression by the persistent melanomas. This point was substantiated by the expression of MHC class I antigens by melanomas persisting in mice treated with IL-2-secreting, melanoma-antigen-negative LM cells (LM-IL-2); it was equivalent to that of melanomas in untreated mice. The involvement of MHC class I antigens in the immune resistance of persistent melanoma cells from mice treated with the melanoma-autigen-positive immunogens was indicated by the effect of interferon (IFN) orN-methyl-N-nitro-N-nitrosoguanidine (MNNG) on the susceptibility of the cells to anti-melanoma CTL. Treatment of the resistant melanomas with IFN or MNNG stimulated MHC class I antigen expression and restored the cells' sensitivity to CTL from mice immunized with IL-2-secreting or nonsecreting, melanoma-antigen-positive cellular immunogens. Prior treatment of the treated cells with antibodies to MHC class I determinants inhibited the cells' susceptibility to CTL from mice immunized with RLBA-IL-2 cells. 相似文献
12.
A non-dialyzable extract of fresh spinach leaves exhibited a strong antioxidant activity towards oxidation of linoleic acid and suppressed the melanin formation of a mouse melanoma cell line, B16 melanoma 4A5, without any significant effect on the proliferation of cells. 相似文献
13.
David G. Thomassen 《In vitro cellular & developmental biology. Animal》1993,29(6):498-504
Summary Factors regulating the proliferation of normal, preneoplastic, and neoplastic rat tracheal epithelial (RTE) cells were investigated
to identify changes taking place during the progression of RTE cells to neoplasia. Normal RTE cells exhibit clonal proliferation
in a serum-free medium containing pituitary extract, serum albumin, cholera toxin, epidermal growth factor, hydrocortisone,
and insulin. All combinations of these six factors were examined for their abilities to support clonal proliferation of normal,
preneoplastic, and neoplastic RTE cells. In general, preneoplastic RTE cells required fewer factors for proliferation than
normal RTE cells, and neoplastic cells required fewer factors than preneoplastic cells. A common pattern of reductions has
been identified in the growth factors required for the clonal proliferation of preneoplastic vs. normal RTE cells and for
neoplastic vs. preneoplastic and normal RTE cells. Normal RTE cells exhibit clonal proliferation in a serum-free medium supplemented
with a minimum of six factors: bovine serum albumin, bovine pituitary extract, cholera toxin, epidermal growth factor, hydrocortisone,
and insulin. Preneoplastic RTE cells exhibit clonal proliferation in a serum-free medium supplemented with four factors: bovine
serum albumin, bovine pituitary extract, hydrocortisone, and insulin. Finally, neoplastic RTE cells exhibit clonal proliferation
in a serum-free medium supplemented with two factors: bovine serum albumin and bovine pituitary extract. These results suggest
that the progression of RTE cells to neoplasia is associated with a series of changes in regulatory pathways that control
cell proliferation. 相似文献
14.
Vito W. Rebecca Jessie Villanueva Marie R. Webster 《Pigment cell & melanoma research》2023,36(6):576-582
To commemorate the 20th Anniversary of the Society of Melanoma Research and the first International Melanoma Research Congress held in June of 2003, we have described in brief, how the Society for Melanoma Research (SMR) began, the purpose, goals, and governance of the SMR, and how the society has evolved to support new melanoma researchers. In celebration of the immense progress in treating melanoma patients over the last 20 years and the impact of the SMR on these advances, we have highlighted memories and insight from early SMR members and founders. 相似文献
15.
Gretchen M. Alicea Jessie Villanueva Marie R. Webster Vito W. Rebecca 《Pigment cell & melanoma research》2023,36(6):594-601
Upon the 20th Anniversary of the Society for Melanoma Research, we highlight the perspectives of patients aiming to help improve future experiences, outcomes, and their quality of life over the next 20 years. Five melanoma patients generously shared their inspiring and enlightening stories of diagnosis, treatment, and outcomes. Many patients had excellent medical teams that synergistically worked together to provide an accurate diagnosis, effective treatment options, and supportive care. However, it is clear that health inequities persist in communities where people of color are predominant, affecting early detection, patient experience, and outcomes. These stories shed light on the unique challenges faced by patients and how the lack of melanoma awareness and adequate resources, especially in communities of color or low socioeconomic status, can contribute to disparate outcomes in melanoma care. We expect that these stories will raise awareness about the progress in melanoma treatment but also the existent disparities in melanoma diagnosis and treatment and the importance of early detection and prevention. 相似文献
16.
Junqi Liu Jin Zhang Narasimha M. Beeraka Kuo Chen Mikhail Y. Sinelnikov Prasath Manogaran Gurupadayya Bannimath Vladimir N. Nikolenko Ruitai Fan 《Pigment cell & melanoma research》2023,36(3-4):268-287
Several research reports delineated the significant role of miRNAs in cancer proliferation, and their modulatory role in cancer mitigation, and drug resistance. Melanoma cells have been acquiring stemness to several chemotherapeutic agents through drug efflux proteins, epigenetic modulation, and DNA repair. miRNAs could be applied as novel therapeutic modalities for treating several kinds of cancers to modulate these mechanisms involved in stemness. Nanocarriers to carry these tumor-targeting miRNAs to modulate stemness are a prominent strategy to overcome their low penetrability, minimal stability, and nonspecificity. We have searched several public databases such as PubMed, Medline, Google scholar, and NLM and obtained the information pertinent to the miRNA-based nanocarrier systems to target stemness through epigenetic modulation in melanomas. This review delineates that various miRNAs can modulate the stemness in melanomas by specific intricate epigenetic signaling, and other cell-based signaling mechanisms. Specific nanocarrier formulations with specific miRNAs are optimal methods to deliver these miRNAs in order to achieve significant entrapment efficiency, loading efficiency, and stability. Furthermore, the combinatorial regimen of FDA-approved chemotherapeutic molecules with tumor-targeting miRNAs and chemotherapy combined with nanocarriers can efficiently deliver the utmost therapeutic window by targeting tumor matrix, invasion, metastasis, and angiogenesis in melanomas. Substantial research should focus on the clinical application of this gene therapy in melanomas using these low immunogenic, highly degradable, and biocompatible combinatorial nanotherapeutic regimens. 相似文献
17.
Marie E. Portuallo David Y. Lu Gretchen M. Alicea Joel Bolling Rebecca Lee Jennifer McQuade Allison Betof Warner Michael Davies Ashani Weeraratna Jessie Villanueva Vito W. Rebecca 《Pigment cell & melanoma research》2023,36(5):441-447
The inaugural Diversity and Inclusion in Science Session was held during the 2021 Society for Melanoma Research (SMR) congress. The goal of the session was to discuss diversity, equity, and inclusion in the melanoma research community and strategies to promote the advancement of underrepresented melanoma researchers. An international survey was conducted to assess the diversity, equity, and inclusion (DEI) climate among researchers and clinicians within the Society for Melanoma Research (SMR). The findings suggest there are feelings and experiences of inequity, bias, and harassment within the melanoma community that correlate with one's gender, ethnic/racial group, and/or geographic location. Notably, significant reports of inequity in opportunity, discrimination, and sexual harassment demonstrate there is much work remaining to ensure all scientists in our community experience an academic workplace culture built on mutual respect, fair access, inclusion, and equitable opportunity. 相似文献
18.
Tupa Basuroy Megan Dreier Caitlin Baum Thomas Blomquist Robert Trumbly Fabian V. Filipp Ivana L. de la Serna 《Pigment cell & melanoma research》2023,36(1):19-32
Lineage-specific differentiation programs are activated by epigenetic changes in chromatin structure. Melanin-producing melanocytes maintain a gene expression program ensuring appropriate enzymatic conversion of metabolites into the pigment, melanin, and transfer to surrounding cells. During neuroectodermal development, SMARCA4 (BRG1), the catalytic subunit of SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complexes, is essential for lineage specification. SMARCA4 is also required for development of multipotent neural crest precursors into melanoblasts, which differentiate into pigment-producing melanocytes. In addition to the catalytic domain, SMARCA4 and several SWI/SNF subunits contain bromodomains which are amenable to pharmacological inhibition. We investigated the effects of pharmacological inhibitors of SWI/SNF bromodomains on melanocyte differentiation. Strikingly, treatment of murine melanoblasts and human neonatal epidermal melanocytes with selected bromodomain inhibitors abrogated melanin synthesis and visible pigmentation. Using functional genomics, iBRD9, a small molecule selective for the bromodomain of BRD9 was found to repress pigmentation-specific gene expression. Depletion of BRD9 confirmed a requirement for expression of pigmentation genes in the differentiation program from melanoblasts into pigmented melanocytes and in melanoma cells. Chromatin immunoprecipitation assays showed that iBRD9 disrupts the occupancy of BRD9 and the catalytic subunit SMARCA4 at melanocyte-specific loci. These data indicate that BRD9 promotes melanocyte pigmentation whereas pharmacological inhibition of BRD9 is repressive. 相似文献
19.
摘要 目的:分析铜蓝蛋白(CER)、鳞状细胞癌相关抗原(SCCA)与慢性肾功能衰竭的关系及对病情进展的预测价值。方法:选择我院自2019年4月至2021年4月接诊的169例慢性肾功能衰竭患者作为研究对象,根据24 h尿白蛋白定量分为微量白蛋白尿组(<200 mg/24 h,102例)和大量白蛋白尿组(>200 mg/24 h,67例)。比较两组各项实验室指标及血清CER、SCCA水平,分析CER、SCCA与慢性肾功能衰竭患者肾功能指标的关系。随访12个月,观察病情进展,使用受试者工作特征曲线(ROC)评价血清CER联合SCCA对病情进展的预测效能。结果:大量白蛋白尿组血清肌酐(Scr)、血尿素氮(BUN)水平均明显高于微量白蛋白尿组,肾小球滤过率(GFR)低于微量白蛋白尿组(P<0.05);大量白蛋白尿组血清CER、SCCA水平均高于微量白蛋白尿组(P<0.05);经Pearson相关性分析,慢性肾功能衰竭患者血清CER、SCCA水平均与Scr、BUN呈正相关,与GFR呈负相关(P<0.05);经多因素Logistic回归分析,GFR、CER、SCCA均是慢性肾功能衰竭患者病情进展的独立预测因素(P<0.05);经ROC曲线分析,血清CER联合SCCA预测慢性肾功能衰竭患者病情进展的AUC为0.925,明显大于GFR的0.620(P<0.05)。结论:血清CER、SCCA水平与慢性肾功能衰竭患者肾功能呈负相关,联合预测病情进展效能较好,值得临床予以重视应用。 相似文献
20.
Danuta Sosnowska Andrzej Mysliwski Krystyna Dzierzbicka Aleksander M. Kolodziejczyk 《Biotherapy》1997,10(2):161-168
The modulation of NK activity by muramyl dipeptides derivatives against Ab (amelanotic) Bomirski melanoma and human erythroleukemia
K562 cells was studied in vitro. The stimulatory effect was observed for 3 of 7 muramyl dipeptides: MDP(L-Ala)C921, MDPC857
and L18-MDP(Ala) in relation to cytotoxic activity of NK cells obtained from peripheral blood and spleen of healthy and Ab
Bomirski melanoma bearing hamsters. An increased of cytotoxic activity NK cells isolated from animals before and during the
transplantable phase of the tumor against K562 was found. A similar stimulation was received for NK cells obtained from animals
against their own melanoma cells. The most significant influence of examined MDP derivatives on the cytotoxic activity of
NK cells were obtained from animals between 10 to 12 days of tumor growth. The extent of the modulation of cytotoxic activity
of NK cells was dependent on its initial value both in healthy control and Ab Bomirski melanoma bearing hamsters. If natural
cytotoxic activity was high the stimulatory effect of the examined MDP derivatives was only slightly expressed. 相似文献